Abstract

Phase 1 trials with HA22, a new more active form of BL22 have been initiated in HCL and acute lymphoblastic leukemia. A phase 2 trial with immunotoxin BL22 that targets CD22 on Hairy Cell Leukemia has been completed. 32 patients have been treated and about half of these patients have under gone complete remissions. A phase 1 trial with HA22 in pediatric acute lymphocytec leukemia is open in collaboration with Dr. Alan Wayne, P.O.B. Two phase 1 trials with immunotoxin SS1P given by continuous infusion or Q.O.D. x 3 for mesothelioma, pancreatic cancer and ovarian cancer have been completed. Several minor responses were observed. A phase 2 trial combining SS1P with chemotherapy has opened recently. Phase 1 trials in CLL and CTCL with immunotoxin LMB 2 targeting CD25 are open. A phase 1 trial treating brain tumors with immunotoxin MRI- 1FvPE38 has just opened at Duke in collaboration with Darrel Bigner. A Phase 1 trial treating patients with mesothelioma with monoclonal antibody (MORAB-009) has been completed.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010020-13
Application #
7732964
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2008
Total Cost
$1,026,594
Indirect Cost

  Institution

Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Du, Xing; Beers, Richard; Fitzgerald, David J et al. (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68:6300-5
Onda, Masanori; Beers, Richard; Xiang, Laiman et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105:11311-6
Sampson, John H; Akabani, Gamal; Archer, Gerald E et al. (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320-9
Sterman, Daniel H; Recio, Adri; Carroll, Richard G et al. (2007) A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 13:4456-66
Sampson, John H; Raghavan, Raghu; Provenzale, James M et al. (2007) Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol 188:703-9
Sampson, John H; Brady, Martin L; Petry, Neil A et al. (2007) Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60:ONS89-98;discussion ONS98-9
Sampson, John H; Raghavan, Raghu; Brady, Martin L et al. (2007) Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9:343-53
Ise, Tomoko; Kreitman, Robert J; Pastan, Ira et al. (2006) Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med 44:594-602
Onda, Masanori; Nagata, Satoshi; Ho, Mitchell et al. (2006) Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12:4225-31
Hassan, Raffit; Remaley, Alan T; Sampson, Maureen L et al. (2006) Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447-53

Showing the most recent 10 out of 19 publications